Head-to-head evidence
elecoglipron vs HDG1901
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline
elecoglipron
Developed by AstraZeneca
NCT06579105 · Phase 2 · completed
Participants receiving AZD5004 or placebo were randomized and kept blinded to treatment; a semaglutide comparator arm was open-label but was not part of the primary comparison. The highest dose produced a substantially larger drop in HbA1c than placebo, meeting the trial's main goal.
Next expected readout: May 2028 · NCT07664553 (registry estimate)
HDG1901
Developed by Hangzhou Zhongmei Huadong Pharmaceutical
NCT06739044 · Phase 3 · completed
The trial randomized 494 participants to HDG1901 or active Ozempic treatment, but neither participants nor investigators were blinded. Its primary endpoint was change in HbA1c, a surrogate measure, and the registry does not report whether the comparison met its objective, supporting a moderate evidence grade.
Caveat: source is secondary industry coverage that does not cite the trial registry number; attribution rests on sponsor/program match only.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: elecoglipron's landscape · HDG1901's landscape